James is a senior associate in the commercial team with varied experience across technology related sectors but with a growing focus on the interactive entertainment sector, including through a recent 8 month secondment to Sony PlayStation.
James has to date supported clients across the technology, life sciences and financial services sectors, commonly supporting with their business critical transactions and providing advice on IP and data-related issues. James specialises in particular with matters that have a technology angle, including SaaS and other transformational technology projects.
James enjoys a close relationship with his clients and has embedded himself with clients via a combination of retainers, ongoing support, and recent secondment.
Leading Global Video Game Platform
Eight month secondment at a global leading video game platform and publisher gaining extensive experience supporting the
- First party studios
- Licensed merchandise and peripheral legal teams
Transformational IT
Supported a number of life science SaaS providers with their customer templates and negotiations, and supported a number of clients on the customer-side with procurement of business critical IT systems.
Global Healthcare Retainer
Two year data privacy retainer for a global healthcare company, delivering privacy support on their UKI, EMEA and global operations, including the management of large-scale remedial projects.
Major Retail Contract
Led on the negotiations for the opening of concessions for a retail company in > 700 stores across UK and Ireland, including related wholesale arrangements for supply into Europe.
Various FinTech clients
Supported a number of FinTech clients with their contracting arrangements, including in connection with the development of third party software and APIs.
Global Healthcare Company
Provided data privacy support (including project management) to a global healthcare company on a retainer-basis for UK, EMEA and global issues
Gene therapy biotech
Supported a biotechnology company developing gene therapies with its framework agreements with important third party vendors, including for genetic testing and DNA manufacturing services.
